Structure Therapeutics reported mid‑stage data for its oral GLP‑1 candidate aleniglipron showing up to 15% placebo‑adjusted weight loss in Phase IIb cohorts, reviving investor interest in oral small‑molecule obesity drugs. The company’s readout was accompanied by higher rates of gastrointestinal adverse events, which analysts flagged as the key sensitivity for commercial success. Across two mid‑stage studies, different dosing regimens produced substantial weight reductions but notable nausea and vomiting rates, prompting questions about long‑term tolerability and discontinuation risk. Market commentary compared Structure’s results with competing oral GLP‑1 programs from Novo Nordisk and Eli Lilly, which have reported clinically meaningful weight loss with distinct tolerability profiles. Oral GLP‑1 small molecules aim to replicate peptide agonist benefits without injections; efficacy must be balanced against gastrointestinal tolerability and dosing convenience to secure broad uptake.